
Novartis investigational CAR-T therapy gets FDA priority review
pharmafile | March 30, 2017 | News story | Sales and Marketing |Â Â CTL019, FDA, Novartis, leukaemiaÂ
Novartis’ investigational chimeric antigen receptor T cell (CAR-T) therapy CTL019 (tisagenlecleucel-T) has been awarded has been awarded priority review by the FDA for the treatment of relapsed and refractory B-cell acute lymphoblastic leukaemia (ALL) in pediatric and young adult patients, the company has announced.
This is the first CAR-T therapy submission for Novartis, and the news puts it ahead of closest rival Kite Pharma.
82% of patients administered with CTL019 showed complete remission either with or without incomplete blood count recovery within three months in a recent Phase 2 trial, with an estimated 60% relapse-free after six months. CAR-T therapies function through the alteration of a patient’s own T-cells, which are then integrated back into the body to target and destroy cancer cells.
Novartis expects that the treatment could generate revenues in excess of $1 billion once it hits the market.
“With CTL019, Novartis is at the forefront of the science and development of immunocellular therapy as a potential new innovative approach to treating certain cancers where there are limited options,” remarked Vas Narasimhan, Novartis Head of Drug Development.
Matt Fellows
Related Content

FDA grants De Novo authorisation to light-filtering device for migraine
The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …

Scotland starts newborn screening for SMA
As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …

EndoCyclic New Drug application approved by US FDA for endometriosis treatment
EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved …






